Captopril pretreatment augments diabetogenic response to streptozotocin administration: experimental in vivo rat model

Future Journal of Pharmaceutical Sciences

Table 2 Timeline changes in fasting blood sugar, estimated blood glucose 30 min, 60 min, and 120 min (mg/dl) after IPGTT in all studied groups

	Control	STZ-30	STZ-30-Cap	STZ-40	STZ-40-Cap	STZ-50	STZ-50-Cap
Fasting	88.17 ± 1.17	198.17 ± 7.28*	355.5 ± 6.35*#	222.5 ± 10.39*$	380.5 ± 3.94*#€	345 ± 48.2*#€¥	490 ± 10.49*#$€¥@
30 min	144.5 ± 10.56	239.83 ± 9.26*	436.33 ± 22.43*#	259.17 ± 9.35*$	498.83 ± 15.99*#$€	414 ± 28.48*#€¥	487.67 ± 4.97*#$€¥@
60 min	172 ± 3.79	231.5 ± 6.5*	466.67 ± 4.46*#	246.5 ± 3.21*$	523.83 ± 8.84*#$€	421.33 ± 25.15*#$€¥	481.17 ± 9*#€¥@
120 min	116.83 ± 2.64	214.5 ± 4.14*	387.5 ± 82.13*#	227.17 ± 8.18*$	490 ± 5.37*#$€	385.5 ± 20.27*#€¥	506.5 ± 1.38*#$€@

Data presented by mean ± SD No = 6
Statistical analysis was done using one-way ANOVA test followed by Tukey–Kramer post hoc test
*denotes significant difference compared to control, # denotes significant difference compared to STZ-30, $ denotes significant difference compared to STZ-30-Cap, € denotes significant difference compared to STZ-40, ¥ denotes significant difference compared to STZ-40-Cap, and @ denotes significant difference compared to STZ-50
IPGTT Intraperitoneal glucose tolerance test, STZ Streptozotocin, Cap Captopril